Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination

Li-Jun Duan; Wen-Guo Jiang; Zhuang-Ye Wang; Lin Yao; Ka-Li Zhu; Qing-Chuan Meng; Bao-Shan Wang; Li-Bo Li; Guo-Lin Wang; Mai-Juan Ma

iScience (Sep 2022)

Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination

Li-Jun Duan,
Wen-Guo Jiang,
Zhuang-Ye Wang,
Lin Yao,
Ka-Li Zhu,
Qing-Chuan Meng,
Bao-Shan Wang,
Li-Bo Li,
Guo-Lin Wang,
Mai-Juan Ma

Affiliations

Li-Jun Duan: State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
Wen-Guo Jiang: Jining Center for Disease Control and Prevention, Jining, China
Zhuang-Ye Wang: Dezhou Center for Disease Control and Prevention, Dezhou, China
Lin Yao: State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
Ka-Li Zhu: State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
Qing-Chuan Meng: Ningjin County Community Health Service Center, Dezhou, China
Bao-Shan Wang: Decheng District Center for Disease Control and Prevention, Dezhou, China
Li-Bo Li: Jining Center for Disease Control and Prevention, Jining, China
Guo-Lin Wang: State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
Mai-Juan Ma: State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China; Corresponding author

Journal volume & issue: Vol. 25, no. 9
p. 104886

Abstract

Read online

Summary: The emergence of the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant has raised questions regarding resistance to neutralizing antibodies elicited by natural infection or immunization. We examined the neutralization activity of sera collected from previously SARS-CoV-2-infected individuals and SARS-CoV-2 naive individuals who received BBIBP-CorV or CoronaVac to BA.1 and the earlier variants Alpha, Beta, and Delta. Both sera from convalescent patients over three months after infection and two-dose BBIBP-CorV or CoronaVac vaccine recipients barely inhibited BA.1, less effectively neutralized Beta and Delta, and moderately neutralized Alpha. However, administering a single dose of BBIBP-CorV or CoronaVac in previously infected individuals or a third dose booster vaccination of BBIBP-CorV or CoronaVac in previously vaccinated individuals enhances neutralizing activity against BA.1 and other variants, albeit with a lower antibody titer for BA.1. Our data suggest that a booster vaccination is important to broaden neutralizing antibody responses against the variants.

Immune response and virology

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords